• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Critical Thought

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-03-02-2006
Volume 0
Issue 0

IN OUR APRIL 2006 ISSUE, we will explore the results of a reader study—a" pulse check" as we think of it—on the topics of promotional programs, meeting spend, and compliance, cosponsored by Maritz Travel and Pharmaceutical Executive. The study asked industry leaders about their perceptions of their companies' physician meetings in terms of audience, format, and budget, as well as their views on compliance regulations.

IN OUR APRIL 2006 ISSUE, we will explore the results of a reader study—a" pulse check" as we think of it—on the topics of promotional programs, meeting spend, and compliance, cosponsored by Maritz Travel and Pharmaceutical Executive. The study asked industry leaders about their perceptions of their companies' physician meetings in terms of audience, format, and budget, as well as their views on compliance regulations. A total of 61 readers involved in compliance monitoring or management of promotional program budgets within the pharmaceutical industry responded.

Because of the small sample and non-scientific nature of the sampling, the results may not be representative of all Pharm Exec readers. Findings are more qualitative than quantitative, but they help to tell a story even without providing significant statistics. They begin to provide a picture of what your fellow industry executives believe.

Some Highlights Include:

In-person meetings and one-on-one sales calls are the most commonly used meeting formats. Respondents reported that these meeting formats are most effective for conveying product information and gaining strong physician participation.

Many respondents feel that their company is doing only an average job of reaching the right audience and getting a good turnout for their promotional meetings, so there is still much room for improvement.

In general, study respondents feel that pharma companies have taken recent changes in compliance regulations very seriously.

• Two-thirds of respondents agree that the pharma industry is strictly following compliance regulations.

• Respondents report having dedicated compliance departments and legal departments to handle issues related to compliance requests.

On average, companies received 24 compliance requests during the past year; three out of five came from a state, and the rest from federal agencies.

Stay tuned for more info in the April 2006 issue of Pharm Exec.

Recent Videos
Related Content